STOCK TITAN

Nephros to Present at MicroCap Rodeo Best Ideas Bowl on October 13th at 11:30 AM ET

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SOUTH ORANGE, NJ, Oct. 07, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually on October 13th – 16th, 2020.

Nephros is scheduled to present on October 13th at 11:30 AM ET, with one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay: https://www.webcaster4.com/Webcast/Page/2134/37947.

For additional information, request an invitation or to schedule a one-on-one meeting, please register at https://microcaprodeo.com/.

About Nephros

Nephros is a commercial-stage company that develops and markets high performance water purification products and pathogen detection systems for medical and commercial markets.

Nephros ultrafilters are used in hospitals, medical clinics, and commercial facilities to retain bacteria and viruses from water, providing barriers that aid in infection control for showers, sinks, and ice machines. Nephros ultrafilters are also used in dialysis centers to aid in the removal of endotoxins and other biological contaminants from water and bicarbonate concentrate in hemodialysis machines. 

Nephros pathogen detection systems, including the PluraPath™, SequaPath™, and DialyPath™ systems, provide data on water-borne biological content to medical and water quality professionals. Our products integrate Nephros ultrafilters with quantitative polymerase chain reaction (qPCR) technology to deliver actionable water pathogen information in real time.

Nephros commercial filters, including AETHER™ brand filters, improve the taste and odor of water, and reduce scale build-up in downstream equipment. Nephros and AETHER™ products are used in the health care, food service, hospitality, and convenience store markets.

For more information about Nephros, please visit its website at www.nephros.com.

About the MicroCap Rodeo Best Ideas Bowl

The MicroCap Rodeo is back with its first ever “Best Ideas Bowl”. This conference is a virtual conference that brings you the top 25 best ideas from the buy side. Qualified institutional investors recommended each of the 25 companies represented as one of their best ideas. Those of you who attended the 2019 MicroCap Rodeo in Austin, Texas, know that we’re focused on alpha. The Best Ideas Bowl is sure to have some big winners too.

Investor Relations Contact:
Kirin Smith, President
PCG Advisory, Inc.
(646) 863-6519
ksmith@pcgadvisory.com

Media Contact:
Bill Douglass
Gotham Communications, LLC
(646) 504-0890
bill@gothamcomm.com

Company Contact:
Andy Astor, President and CEO
Nephros, Inc.
(201) 345-0824
andy@nephros.com

Nephros, Inc.

NASDAQ:NEPH

NEPH Rankings

NEPH Latest News

NEPH Stock Data

24.88M
5.62M
11.96%
40.29%
0.02%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SOUTH ORANGE

About NEPH

nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: • filtration – as low as 5 nanometers • flow rate – minimal disruption • filter life – up to 12 months nephros was founded in 1997, by healthcare professionals affiliated with columbia university medical center, initially to address the needs of chronic renal failure patients. the company has developed an alternative to current hemodialysis therapy known as mid-dilution hemodiafiltration (mid-hdf). nephros’ proprietary blood purification technologies enable mid-hdf to be offered to chronic renal failure patients. nephros mid-dilution fil